EUVIMEDEUVIMED entdecken
Crossref

Rational Design, Synthesis, and Structure–Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836

Andrew G Cole iD, Steven G Kultgen iD, Nagraj Mani, Kristi Yi Fan iD, Andrzej Ardzinski, Kim Stever, Bruce D Dorsey, Eugen F Mesaros iD, Emily P Thi iD, Ingrid Graves iD, Sunny Tang, Troy O Harasym und 4 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01568 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Andrew G Cole und 15 weiteren Autor:innen. Beteiligte Einrichtung: Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, Pennsylvania 18974, United States. Hauptthemen laut MEDLINE: Hepatitis B virus, Antiviral Agents, Drug Design. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Arbutus Biopharma, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhibition of Hepatitis B Virus (HBV) replication by small molecules that modulate capsid assembly and the encapsidation of pgRNA and viral polymerase by HBV core protein is a clinically validated approach toward the development of new antivirals. Through definition of a minimal pharmacophore, a series of isoquinolinone-based capsid assembly modulators (CAMs) was identified. Structural biology analysis revealed that lead molecules possess a unique binding mode, exploiting electrostatic interactions with accessible phenylalanine and tyrosine residues. Key analogs demonstrated excellent primary potency, absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetic properties, and efficacy in a mouse model of HBV. The optimized lead also displayed potent inhibition of capsid uncoating in HBV-infected HepG2 cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP) receptor, affecting the generation of HBsAg and cccDNA establishment. Based on these results, isoquinolinone derivative AB-836 was advanced into clinical development. In Phase 1b trials, AB-836 demonstrated >3 log10 reduction in serum HBV DNA, however, further development was discontinued due to the observation of incidental alanine aminotransferase (ALT) elevations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B virusAntiviral AgentsDrug DesignHumansStructure-Activity RelationshipAnimalsMiceHep G2 CellsCapsidCapsid ProteinsIsoquinolinesQuinolonesVirus Assembly

Substanzen

Antiviral AgentsCapsid ProteinsIsoquinolinesQuinolones

Autor:innen und Institutionen

  • Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, Pennsylvania 18974, United States.
  • Xtal BioStructures Inc., 12 Michigan Drive, Natick, Massachusetts 01760, United States.

ORCID-Profile: Andrew G Cole, Steven G Kultgen, Kristi Yi Fan, Eugen F Mesaros, Emily P Thi, Ingrid Graves, Amy C H Lee, Robert K Suto

Förderung

  • Arbutus Biopharma, Inc.

Zitieren

APA

Cole, A. G., Kultgen, S. G., Mani, N., Fan, K. Y., Ardzinski, A., Stever, K., Dorsey, B. D., Mesaros, E. F., Thi, E. P., Graves, I., Tang, S., Harasym, T. O., Lee, A. C. H., Olland, A., Suto, R. K., & Sofia, M. J. (2024). Rational Design, Synthesis, and Structure–Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01568

Vancouver

Cole AG, Kultgen SG, Mani N, Fan KY, Ardzinski A, Stever K, et al. Rational Design, Synthesis, and Structure–Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01568

BibTeX
@article{Cole2024,
  author = {Cole, Andrew G and Kultgen, Steven G and Mani, Nagraj and Fan, Kristi Yi and Ardzinski, Andrzej and Stever, Kim and Dorsey, Bruce D and Mesaros, Eugen F and Thi, Emily P and Graves, Ingrid and Tang, Sunny and Harasym, Troy O and Lee, Amy C H and Olland, Andrea and Suto, Robert K and Sofia, Michael J},
  title = {Rational Design, Synthesis, and Structure–Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01568}
}
Kostenlos starten →